Peptide Comparison
TabimorelinvsCJC-1295 (No DAC)
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
A modified growth hormone-releasing hormone that boosts your body's natural GH pulses for better recovery, deeper sleep, and improved body composition.
At a Glance
Quick
comparison
Dose Range
Tabimorelin
100–500 mg
CJC-1295 (No DAC)
100–300 mcg
Frequency
Tabimorelin
Once daily
CJC-1295 (No DAC)
Once daily
Administration
Tabimorelin
Oral (capsule or solution)
CJC-1295 (No DAC)
Subcutaneous injection
Cycle Length
Tabimorelin
4-6 weeks
CJC-1295 (No DAC)
8-12 weeks
Onset Speed
Tabimorelin
Moderate (1-2 weeks)
CJC-1295 (No DAC)
Moderate (1-2 weeks)
Evidence Level
Tabimorelin
Moderate human trials (Phase 1-2)
CJC-1295 (No DAC)
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Growth Hormone Stimulation
Convenience & Compliance
Selectivity & Safety Profile
GH Stimulation
Sleep Quality
Recovery Support
Technical Data
Compound
specifications
Tabimorelin
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 g/mol
Half-Life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS Number
193079-69-5
CJC-1295 (No DAC)
Molecular Formula
C152H252N44O42
Molecular Weight
3367.9 g/mol
Half-Life
30 minutes to 2 hours
Bioavailability
~100% (subcutaneous)
CAS Number
863288-34-0
Protocols
Dosing
tiers
Tabimorelin
CJC-1295 (No DAC)
Applications
Best
suited for
Tabimorelin
+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
+Orally active—no injections required, making it convenient for daily use
+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
+Well-tolerated in short-term human studies with generally mild adverse effects
CJC-1295 (No DAC)
Natural Growth Hormone Optimization
Perfect for those wanting to boost their body's own GH production rather than using synthetic growth hormone. Mimics the natural pulsatile release pattern your pituitary uses.
Workout Recovery and Muscle Building
Athletes and fitness enthusiasts use it to accelerate recovery between training sessions, support lean muscle development, and reduce body fat over time.
Sleep Quality Enhancement
Because GH is naturally released during deep sleep, many users report dramatically improved sleep quality with more vivid dreams and feeling more refreshed upon waking.
Anti-Aging and Vitality
As GH levels decline with age, CJC-1295 helps restore more youthful hormone patterns, potentially improving skin quality, energy levels, and overall well-being.
Synergistic Peptide Stacking
Designed to work hand-in-hand with GHRPs like Ipamorelin. When combined, these peptides amplify each other's effects for significantly greater GH release than either alone.
Safety Profile
Side
effects
Tabimorelin
Common
- Headache
- Nausea
- Appetite stimulation
- Dizziness
- Dry mouth
Serious
- Drug-drug interactions via CYP3A4 inhibition
CJC-1295 (No DAC)
Common
- Injection site reactions
- Flushing or warmth
- Water retention
- Increased appetite
Uncommon
- Tingling or numbness
- Headache
Serious
- Allergic reaction
Research Status
Safety
& evidence
Tabimorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Contraindications
- xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- xUntreated thyroid dysfunction
- xUncontrolled diabetes
CJC-1295 (No DAC)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
CJC-1295 without DAC has been studied in Phase 1-2 human clinical trials with a favorable safety profile. The most common side effects are mild and include injection site reactions and temporary flushing. Because it stimulates natural GH release rather than providing exogenous GH, it maintains the body's feedback mechanisms.
Contraindications
- xActive cancer or history of cancer
- xPregnancy or breastfeeding
- xPituitary tumors or disorders
- xHypersensitivity to GHRH analogs
- xDiabetic retinopathy
Decision Guide
Which is
right for you?
Choose Tabimorelin if...
- Stimulating growth hormone production in healthy individuals
- Exploring GH secretagogue mechanisms in research settings
- Patients preferring oral administration over injections
Choose CJC-1295 (No DAC) if...
- Increasing natural growth hormone levels
- Building lean muscle mass
- Improving sleep quality
- Enhancing workout recovery